Study summary · research use only
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This mouse study examined SLU-PP-332, a synthetic agonist of the estrogen-related receptor (ERR) α, β, and γ nuclear receptors previously described as activating an exercise-like physiologic program, in diet-induced obese and ob/ob mouse models of obesity and metabolic syndrome. The authors report that SLU-PP-332 administration reproduced several exercise-associated changes in whole-body metabolism, including increased energy expenditure and fatty acid oxidation, along with decreased fat mass accumulation. The agonist was also associated with reduced obesity and improved insulin sensitivity in these metabolic syndrome models. The authors describe pharmacological ERR activation as a potential approach for metabolic syndrome and obesity, noting exercise itself is described as reducing the risk of premature death from all causes.
Abstract
Physical exercise induces physiologic adaptations and is effective at reducing the risk of premature death from all causes. Pharmacological exercise mimetics may be effective in the treatment of a range of diseases including obesity and metabolic syndrome. Previously, we described the development of SLU-PP-332, an agonist for the estrogen-related receptor (ERR)α, β, and γ nuclear receptors that activates an acute aerobic exercise program. Here we examine the effects of this exercise mimetic in mouse models of obesity and metabolic syndrome. Diet-induced obese or ob/ob mice were administered SLU-PP-332, and the effects on a range of metabolic parameters were assessed. SLU-PP-332 administration mimics exercise-induced benefits on whole-body metabolism in mice including increased energy expenditure and fatty acid oxidation. These effects were accompanied by decreased fat mass accumulation. Additionally, the ERR agonist effectively reduced obesity and improved insulin sensitivity in models of metabolic syndrome. Pharmacological activation of ERR may be an effective method to treat metabolic syndrome and obesity. SIGNIFICANCE STATEMENT: An estrogen receptor-related orphan receptor agonist, SLU-PP-332, with exercise mimetic activity, holds promise as a therapeutic to treat metabolic diseases by decreasing fat mass in mouse models of obesity.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.